Targeted Oncology: Transfusion independence at 24 weeks linked to improved OS on momelotinib in myelofibrosis

Dr. Ruben Mesa, executive director of the Mays Cancer Center, is quoted in this Targeted Oncology story.

Read the story. 



Share This Article!
Article Categories: Cancer, In the News